SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Apple Restores Telegram to App Store After Content Policy Violation 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
SOUTH SAN FRANCISCO, Calif., March 15, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on March 12, 2018, the compensation committee of the Company’s board of directors granted David L. Johnson an option to purchase 55,000 shares of the Company’s common stock with a per share exercise price of $54.05, the closing trading price on the grant date, and a restricted stock unit award for 35,000 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to Mr. Johnson entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock options and restricted stock unit awards described above) for issuance under the Plan, which was approved by the Company’s board of directors in January 2017.
About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
